You are here
Voluntary Recall Issued for a Single Lot of Morphine Sulfate
June 12, 2008
June 10, 2008 -- Ethex Corporation notified healthcare professionals of a voluntary recall of a single lot of morphine sulfate 60 mg extended release tablets (Lot No. 91762) due to a report of a tablet with twice the appropriate thickness. Oversized tablets may contain as much as two times the labeled level of active morphine sulfate. The lot was distributed by Ethex Corporation under an "Ethex" label between April 16th and April 27th of 2008. Opioids such as morphine have life-threatening consequences if overdosed. Consequences can include respiratory depression (difficulty or lack of breathing), and low blood pressure. Many patients for whom this product is prescribed are likely to be highly debilitated with reduced strength or energy as a result of illness, and may be less likely to determine that a tablet is overweight or oversized than an unimpaired individual. If consumers have any questions about the recall, they should call their physician, pharmacist, or other health care provider.
June 09, 2008 - Press Release - Ethex Corp.
Source: Food and Drug Administration
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Old Chemo Drug at High Doses Goads Immune System to Fight Lymphoma
Relapses Reduced By 94%
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels
NCI Study: Radioactive Iodine Associated With Solid Tumors
Findings May Explain Apparent Opioid-Seeking Behavior, Opioid Overuse